NEW YORK – The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has authorized Novartis' Kisqali (ribociclib) in combination with an aromatase inhibitor as a treatment for patients with ...

Cognitive dysfunction has been considered as a morbid condition that may possibly result from aromatase inhibitor therapy, the standard treatment in postmenopausal, estrogen/progesterone receptor ...

During treatment with aromatase inhibitor letrozole, assessment of liver function, lipids, hemoglobin and hematocrit were performed every 6-12 months. Hormonal analysis was performed at each ...

We read with interest the article by Marie Lund and colleagues published in The Lancet Oncology investigating the association between aromatase inhibitor treatment (AIT) and ischaemic cardiotoxicity ...

Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510282, China ...

Aromatase inhibitors (AIs) are becoming the hormonal treatment of choice for postmenopausal women with early breast cancer. Large, well-controlled clinical studies have established the efficacy ...

In recent years, cancer immunotherapy has made remarkable achievements. Immune checkpoint inhibitors (ICIs) have been used successfully in several types of cancer in the past decade. However, expanded ...

State Key Laboratory of Microbial Metabolism and School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China Zhangjiang Institute for Advanced Study, Shanghai Jiao ...